+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinocerebellar Ataxia (SCA) Pipeline Analysis 2019 (H1)

  • ID: 4801796
  • Report
  • May 2019
  • Region: Global
  • 80 pages
  • Knowledge Sourcing Intelligence LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bioblast Pharma Ltd.
  • Biohaven Pharmaceutical
  • Cadent Therapeutics
  • Ionis
  • Lacerta Therapeutics
  • Shire
  • MORE
Spinocerebellar Ataxia (SCA) Pipeline Analysis report covers approximately 10 drugs currently in different phases of development. Spinocerebellar Ataxia (SCA) is a term referring to the group of genetic autosomal dominant diseases that causes degenerative changes in the cerebellum. Symptoms of the disease are an uncoordinated walk, decreased hand-to-eye coordination, dysarthria (slurred or abnormal speech), improper vision and involuntary eye movement and difficulty in processing, learning and remembering information. The disease is diagnosed through genetic testing and treatment options vary as per the type of SCA and signs and symptoms of SCA. The classification is done according to the mutated gene responsible for the type of ataxia and is describes as SCA followed by the number (SCA1 till SCA40).

The report provides Spinocerebellar Ataxia (SCA) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are Kissei Pharmaceutical Co., Ltd., Steminent Biotherapeutics Inc., and Wave Life Sciences among others.

Scope:
  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bioblast Pharma Ltd.
  • Biohaven Pharmaceutical
  • Cadent Therapeutics
  • Ionis
  • Lacerta Therapeutics
  • Shire
  • MORE
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
  • Drug Name
  • Generic Name
  • Synonyms
  • Company
  • Collaborator
  • Route of administration
  • Target
  • Mechanism of Action
  • Technology
  • Molecule type
  • CAS Number
  • Weight
  • Chemical Formula
  • IUPAC name
  • ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling
6.1. Lacerta Therapeutics
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. Recent Developments
6.1.5. SWOT
6.2. Kissei Pharmaceutical Co., Ltd.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. Recent Developments
6.2.5. SWOT
6.3. Biohaven Pharmaceutical
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. Recent Developments
6.3.5. SWOT
6.4. Steminent Biotherapeutics Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. Recent Developments
6.4.5. SWOT
6.5. Bioblast Pharma Ltd.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. Recent Developments
6.5.5. SWOT
6.6. Cadent Therapeutics
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. Recent Developments
6.6.5. SWOT
6.7. Vybion
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. Recent Developments
6.7.5. SWOT
6.8. Wave Life Sciences
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. Recent Developments
6.8.5. SWOT
6.9. Shire
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. Recent Developments
6.9.5. SWOT
6.10. Ionis
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. Recent Developments
6.10.5. SWOT
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Lacerta Therapeutics
  • Kissei Pharmaceutical Co., Ltd.
  • Biohaven Pharmaceutical
  • Steminent Biotherapeutics Inc.
  • Bioblast Pharma Ltd.
  • Cadent Therapeutics
  • Vybion
  • Wave Life Sciences
  • Shire
  • Ionis
Note: Product cover images may vary from those shown
Adroll
adroll